Managing Director
Mumbai Office | nitin.lath@torreya.com | +91 99-8755-6055
Nitin Lath, a Managing Director in Torreya’s Mumbai office, has two decades of investment banking experience analyzing and advising Indian companies across all life sciences sectors.
Before joining Torreya in 2016, Nitin led the healthcare banking division of IDFC Securities and was a member of life sciences investment banking teams at Avendus Capital and Yes Bank Ltd. Earlier in his career, while at IDBI Bank Ltd., he was responsible for the life sciences credit portfolio, and he was a member of the structured finance team at ICICI Bank Ltd.
Highlights of Nitin’s life sciences transaction work include advising Dr. Reddy’s on its acquisition of drug-delivery company Octoplus, advising Shasun Pharma in its merger with Strides, advising Greater Pacific Capital on the sale of its stake in Torrent, and advising Bain Capital on its acquisition of Blackstone’s stake in Emcure Pharma.
Nitin earned his B.A in commerce from Mumbai University. He is also a Chartered Accountant from ICAI and a Chartered Financial Analyst. Nitin is fluent in English and Hindi.
|
Sale of domestic brands to |
|
September 2021
|
![]() |
Investment by |
![]() |
$13.5 million
August 2021
|
![]() |
Sale of 100% equity stake to |
![]() |
$106 million + milestones
June 2021
|
![]() |
Majority recap by |
![]() |
$125 million
April 2019
|
![]() |
and![]() purchase of majority stake in |
![]() |
December 2018
|
![]() |
Divestment of Leiden, Netherlands facility to |
![]() |
December 2022
|
![]() |
Acquisition of bulk formulation manufacturing facility from |
![]() |
October 2022
|
![]() |
Investment by |
|
$68 million
June 2022
|
|
Investment by |
![]() |
December 2021
|
![]() |
Sale of U.S. and Canadian rights for ELYXYB to |
![]() |
August 2021
|
![]() |
Acquisition of Akorn India Limited, a subsidiary of |
![]() |
August 2020
|
![]() |
collaboration for its gynecological business in Nepal and India with |
![]() |
January 2020
|
![]() |
BE Vaccines SAS sale to Clean Cells, a portfolio company of |
![]() |
Undisclosed
March 2019
|
![]() |
Acquisition of API facility from |
![]() |
December 2017
|
![]() |
Sale of selected generic brands to |
![]() |
June 2017
|
![]() |
Sale of stake of |
![]() |
$35 million
Joint Sell-Side Advisor May 2017
|
![]() |
Sale of India women's health business to |
![]() |
April 2017
|
![]() |
Sale of equity stake to |
![]() |
$33 million
November 2016
|